The loan carries 10% simple interest, may be prepaid without penalty, is extendable for an additional six months and includes warrants to purchase 390,000 ...
GSK4532990 is being developed under the November 2021 exclusive license agreement between Arrowhead and GSK. GSK received an exclusive license to develop a...
The oversubscribed financing was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Canc...
Full Year 2022 Financial Results All comparisons are made on a year-over-year basis. Revenues. We generated $969,783 and $355,797 in revenues for the y...
The EIC investment was made through its Accelerator Fund, designed to support small and medium enterprises (SMEs), in particular start-ups and spin-out com...
"We are running a comprehensive development program for tarcocimab tedromer with topline data from four Phase 3 studies planned for 2023: two for the long-...
© 2025 Biopharma Boardroom. All Rights Reserved.
